Nucor earnings beat by $0.08, revenue fell short of estimates
LAUSANNE, Switzerland - ADC Therapeutics SA (NYSE: ADCT), a biotechnology company with a market capitalization of $355 million and annual revenue of $76 million, reported updated Phase 2 data showing its antibody drug conjugate ZYNLONTA achieved an 85% overall response rate and 69% complete response rate in treating relapsed/refractory marginal zone lymphoma (r/r MZL).
The data, presented at the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland, comes from a multicenter investigator-initiated trial led by Dr. Izidore S. Lossos of the Sylvester Comprehensive Cancer Center. According to InvestingPro data, ADC Therapeutics has shown strong market performance with a 79% return over the past six months, though analysts note the company faces profitability challenges.
According to the company, 17 of 18 patients who achieved complete response maintained this status, with the longest duration reaching 27 months from treatment initiation. The trial enrolled 27 adult patients with r/r MZL who had received at least one prior line of systemic therapy, with 26 patients evaluable for response.
The study data showed progression-free survival was 92.9% at 12 months. Among patients who progressed within 24 months of first-line therapy (POD24), the complete response rate was 61.5%.
ZYNLONTA was generally well tolerated with adverse events consistent with its known safety profile. Most adverse events were grade 1 or 2, though grade 3 and 4 events occurred in 16 and 2 patients respectively, including neutropenia, RSV lung infection and hyponatremia. Three patients required dose reduction and one discontinued treatment.
The trial has expanded to additional cancer centers to accelerate enrollment to 50 patients with r/r MZL.
ZYNLONTA is currently FDA-approved for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
This information is based on a press release statement from ADC Therapeutics. While the company maintains healthy liquidity with a current ratio of 4.46, InvestingPro analysis reveals several additional insights about the company’s financial health and market position. For deeper analysis and access to 10+ exclusive ProTips, including detailed profitability metrics and growth forecasts, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, ADC Therapeutics has reported significant developments concerning its cancer treatment efforts. The company announced promising results from its LOTIS-7 Phase 1b trial, where the combination of ZYNLONTA and glofitamab showed a 93.3% overall response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This data led Guggenheim to raise its price target for ADC Therapeutics to $10, citing a higher probability of success for the LOTIS-7 opportunity. However, following the release of fourth-quarter earnings showing ZYNLONTA sales of $16.4 million, which fell short of expectations, Guggenheim adjusted its price target back to $7 while maintaining a Buy rating.
In addition, ADC Therapeutics secured $100 million through a private placement, with proceeds aimed at supporting the clinical development and commercialization of ZYNLONTA. The company plans to use the funds to advance its pipeline, including the LOTIS-5 Phase 3 trial, with results anticipated by the end of 2025. As part of its restructuring plan, ADC Therapeutics announced a 30% reduction in its workforce and the closure of its UK operations. These changes are expected to extend the company’s cash runway into 2028, positioning it for long-term growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.